OpenURL Connection Search

Select item for more details and to access through your institution.

The Marshall article reviewed.
Published in:
2005
By:
- Laheru D;
- Jaffee EM
Publication type:
Journal Article
Novel vaccines for the treatment of gastrointestinal cancers.
Published in:
2005
By:
- Marshall JL;
- Schlom J;
- Arlen PM;
- Gulley JL;
- Laheru D;
- Jaffee EM;
- Kelsen DP
Publication type:
Journal Article
Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.
Published in:
Investigational New Drugs, 2018, v. 36, n. 6, p. 1037, doi. 10.1007/s10637-018-0600-2
By:
- Finn, R. S.;
- Ahn, D. H.;
- Javle, M. M.;
- Tan, B. R.;
- Weekes, C. D.;
- Bendell, J. C.;
- Patnaik, A.;
- Khan, G. N.;
- Laheru, D.;
- Chavira, R.;
- Christy-Bittel, J.;
- Barrett, E.;
- Sawyer, M. B.;
- Bekaii-Saab, Tanios S.
Publication type:
Article
Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival.
Published in:
JOP Journal of the Pancreas, 2011, v. 12, n. 4, p. 434
By:
- Arnaoutakis, G. J.;
- Rangachari, D.;
- Laheru, D. A.;
- Iacobuzio-Donahue, C. A.;
- Hruban, R. H.;
- Herman, J. M.
Publication type:
Article
A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.
Published in:
British Journal of Cancer, 2015, v. 112, n. 1, p. 24, doi. 10.1038/bjc.2014.515
By:
- Wilky, B A;
- Rudek, M A;
- Ahmed, S;
- Laheru, D A;
- Cosgrove, D;
- Donehower, R C;
- Nelkin, B;
- Ball, D;
- Doyle, L A;
- Chen, H;
- Ye, X;
- Bigley, G;
- Womack, C;
- Azad, N S
Publication type:
Article
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.
Published in:
2010
By:
- Garrido-Laguna, I;
- Tan, A. C.;
- Uson, M;
- Angenendt, M;
- Ma, W. W.;
- Villaroel, M. C.;
- Zhao, M;
- Rajeshkumar, N. V.;
- Jimeno, A;
- Donehower, R;
- Iacobuzio-Donahue, C;
- Barrett, M;
- Rudek, M. A.;
- Rubio-Viqueira, B;
- Laheru, D;
- Hidalgo, M
Publication type:
journal article
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).
Published in:
Cancer Chemotherapy & Pharmacology, 2014, v. 74, n. 2, p. 379, doi. 10.1007/s00280-014-2499-4
By:
- Dragovich, T.;
- Laheru, D.;
- Dayyani, F.;
- Bolejack, V.;
- Smith, L.;
- Seng, J.;
- Burris, H.;
- Rosen, P.;
- Hidalgo, M.;
- Ritch, P.;
- Baker, A.;
- Raghunand, N.;
- Crowley, J.;
- Hoff, D.
Publication type:
Article

Found: 7

The Marshall article reviewed.

Novel vaccines for the treatment of gastrointestinal cancers.

Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.

Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival.

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).